.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Argus Health
Covington
Deloitte
Merck
Moodys
US Army
Harvard Business School
Teva
Baxter

Generated: December 13, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,010,090

« Back to Dashboard

Claims for Patent: 5,010,090

Title: N-(butenyl substituted) azaheterocyclic carboxylic acids
Abstract:1-Aminobut-3-en derivatives having optionally substituted furanyl, thienyl, pyridyl and/or pyrrolyl in the 4-position and 3-carboxypiperidin-1-yl, 3-carboxytetrahydropyrid-1-yl or 3 carboxymethylpyrrolidin-1-yl in the 1-position potentiate GABA-ergic neurotransmission.
Inventor(s): Gronvald; Frederik C. (Vedbaek, DK), Braestrup; Claus (Roskilde, DK)
Assignee: Novo Nordisk A/S. (Bagsvaerd, DK)
Application Number:07/254,557
Patent Claims: 1. A compound of formula I ##STR9## wherein R.sup.1 and R.sup.2 are the same or different and each represents a substituted or unsubstituted, thien-2-yl, thien-3-yl, pyrrol-2-yl or pyrrol-3-yl wherein the substitution is with at least one of C.sub.1-7 alkyl, bromo, chloro, or fluoro and at least one of said R.sup.1 and R.sup.2 is thien-2-yl substituted at least at the 3-position or pyrrol-2-yl substituted at least at the 1-position with C.sub.1-7 -alkyl, chloro, bromo, or fluoro, and wherein R.sup.3 represents 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl or 3-carboxymethylpyrrolidin-1-yl, and pharmaceutically acceptable salts thereof.

2. A compound of formula I ##STR10## wherein R.sup.1 is 3-methylthien-2-yl, R.sup.2 is 3-methylthien-2-yl and R.sup.1 is nipecotic acid, and pharmaceutically acceptable salts thereof.

3. A compound of formula I ##STR11## wherein R.sup.1 is thien-2-yl, R.sup.2 is 3-methylthien-2-yl and R.sup.3 is guvacine, and pharmaceutically acceptable salts thereof.

4. A compound of formula I ##STR12## wherein R.sup.1 is thien-2-yl, R.sup.2 is 3-methylthien-2-yl and R.sup.3 is nipecotic acid, and pharmaceutically acceptable salts thereof.

5. A compound of formula I ##STR13## wherein R.sup.1 is 3-methylthien-2-yl, R.sup.2 is 3-methylthien-2-yl and R.sup.3 is guvacine, and pharmaceutically acceptable salts thereof.

6. A compound according to the following formula ##STR14## wherein R.sup.1 and R.sup.2 are the same or different and each represents thienyl or pyrrolyl and wherein R.sup.3 represents 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl or 3-carboxymethylpyrrolidin-1-yl, selected from the following:

N-(4,4-Bis(3-methylthien-2-yl)but-3-enyl)guvacine,

N-(4,4-Bis(3-methylthien-2-yl)but-3-enyl)nipecotic acid,

N-(4,4-Bis(3-methylthien-2-yl)but-3-enyl)-.beta.-homoproline,

N-(4-(3-Methylthien-2-yl)-4-(thien-2-yl)but-3-enyl)guvacine,

N-(4-(3-Methylthien-2-yl)-4-(thien-2-yl)but-3-enyl)nipecotic acid,

N-(4-(3-Methylthien-2-yl)-4-(thien-2-yl)but-3-enyl)-.beta.-homoproline

N-(4-(N-methylpyrrol-2-yl)-4-(thien-2-yl)but-3-enyl)guvacine,

N-(4-(N-methylpyrrol-2-yl)-4-(thien-2-yl)but-3-enyl)nipecotic acid,

N-(4-(N-methylpyrrol-2-yl)-4-(thien-2-yl)but-3-enyl)-.beta.-homoproline,

N-(4,4-Bis(N-methylpyrrol-2-yl)but-3-enyl)guvacine,

N-(4,4-Bis(N-methylpyrrol-2-yl)but-3-enyl)nipecotic acid,

N-(4,4-Bis(N-methylpyrrol-2-yl)but-3-enyl)-.beta.-homoproline

N-(4-(3-Bromothien-2-yl)-4-(thien-2-yl)but-3-enyl)-nipecotic acid, and

pharmaceutically acceptable salts thereof.

7. A compound of formula I ##STR15## wherein R.sup.1 and R.sup.2 are the same or different and each represents thienyl, or pyrrolyl, and wherein R.sup.3 represents 3-carboxypiperdin-1-yl,3-carboxy-1,2,5,6-tetrahydropyridin-1-yl or 3-carboxymethyl-pyrrolidin-1-yl, selected from the following:

N-(4,4-Bis(3-Methylthien-2-yl)but-3-enyl)nipecotic acid,

N-(4,4-Bis(4-Methylthien-2-yl)but-3-enyl)nipecotic acid,

N-(4,4-Bis(5-Methylthien-2-yl)but-3-enyl)nipecotic acid,

N-(b 4-(3-Methylthien-2-yl)-4-(4-Methylthien-2-yl)but-3-enyl)nipecotic acid,

N-(4-(3-Methylthien-2-yl)-4-(4-Methylthien-2-yl)but-3-enyl)guvacine,

N-(4-(3-Methylthien-2-yl)-4-(thien-2-yl)but-3-enyl)nipecotic acid,

N-(4-(3-Methylthien-2-yl)-4-(4-thien-2-yl)but-3-enyl)guvacine,

N-(4,4-Bis(N-methylpyrrol-2-yl))but-3-enyl)nipecotic acid,

N-(4,4-Bis(5-chloro-4-methylpyrrol-2-yl))but-3-enyl)nipecotic acid,

N-(4-(3-Methylthien-2-yl)-4-(thien-2-yl)but-3-enyl)-.beta.-homoproline, and

pharmaceutically acceptable salts thereof.

8. Pharmaceutical compositions containing effective amounts of a compound according to the formula I ##STR16## wherein R.sup.1 and R.sup.2 are the same or different and each represents a substituted or unsubstituted thien-2-yl, thien-3-yl, pyrrol-2-yl or pyrrol-3-yl wherein the substitution is with at least one of C.sub.1-7 alkyl, bromo, chloro, or fluoro and at least one of said R.sup.1 and R.sup.2 is thien 2-yl substituted at least at the 3-position or pyrrol-2-yl substituted at least at the 1-position with C.sub.1-7 -alkyl, chloro bromo, or fluoro and wherein R.sup.3 represents 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl or 3-carboxymethyl-pyrrolidin-1-yl, and pharmaceutically acceptable salts thereof.

9. Compositions according to claim 8, characterized in that they contain therein a therapeutically effective dose of from about 25 mg to about 1 g of the compound.

10. A method of inhibiting uptake of .gamma.-amino butyric acid in a subject in need of such a treatment comprising the step of administering to said subject a therapeutically effective dose of a compound according to the formula ##STR17## wherein R.sup.1 and R.sup.2 are the same or different and each represents a substituted or unsubstituted thien-2-yl, thien-3-yl, pyrrol-2-yl or pyrrol-3-yl wherein the substitution is with at least one of C.sub.1-7 alkyl, bromo, chloro, or fluoro and at least one of said R.sup.1 and R.sup.2 is thien-2-yl substituted at least at the 3-position or pyrrol-2-yl substituted at least at the 1-position with C.sub.1-7 -alkyl, chloro, bromo, or fluoro and wherein R.sup.3 represents 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-l-yl or 3-carboxymethylpyrrolidin-1-yl, and pharmaceutically acceptable salts thereof.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Accenture
Chinese Patent Office
Moodys
Cerilliant
Medtronic
Covington
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot